Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00033917 · ClinicalTrials.gov registry record · Phase 3

Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial

A Phase 3 study of Prematurity and Intraventricular Hemorrhage (IVH), sponsored by Yale University.

Completed
Registry status
Phase 3
Development phase
630
Enrollment target
3
Study locations

NCT00033917: Completed Phase 3 study of Prematurity and Intraventricular Hemorrhage (IVH), sponsored by Yale University.

NCT00033917 is a Phase 3 study of Prematurity and Intraventricular Hemorrhage (IVH) that has completed, run by Yale University. The registered enrollment target is 630 participants, above the 181-participant average among 21 other Prematurity trials with a reported enrollment target (248% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00033917, a Phase 3 study of Prematurity and Intraventricular Hemorrhage (IVH), has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 3
Development phase
630 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this multicenter trial is to determine if indomethacin prevents bleeding in the brain of very low birth weight preterm infants.

Primary Outcome

Cranial ultrasounds were performed daily for the first 5 postnatal days; the main outcome measure was intraaventricular hemorrhage (IVH) at 5 days of age

Interventions

  • DRUG placebo
  • DRUG indomethacin

Study Locations (3)

Connecticut

  • Yale University School of Medicine - New Haven

Maine

  • Maine Medical Center - Portland

Rhode Island

  • Brown University School of Medicine - Providence

Trial Details

FieldValue
Enrollment Target 630 participants
Start Date 1989-09
Est. Completion 2012-03
Phase Phase 3
Yale University

1,492 total trials

What the finished NCT00033917 record still lists

NCT00033917 is an interventional study that assigns participants to a tested intervention. The registered 630 participants enrollment target is mid-sized for trials with a published cap, above the 181-participant average among 21 other Prematurity trials with a reported enrollment target (248% higher).

The record links to 4 conditions, with Prematurity appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00033917 reports a single indexed study location in Connecticut, Maine, Rhode Island.

Frequently Asked Questions

What is clinical trial NCT00033917 about?

NCT00033917 is a clinical study titled "Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial". The purpose of this multicenter trial is to determine if indomethacin prevents bleeding in the brain of very low birth weight preterm infants.

What is the current status of trial NCT00033917?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 630 participants. The study started on 1989-09. Estimated completion is 2012-03.

What conditions does trial NCT00033917 study?

This clinical trial studies the following conditions: Prematurity, Intraventricular Hemorrhage (IVH), Bleeding in the Brain, Very Low Birth Weight Infants.

What interventions are being tested in trial NCT00033917?

The interventions under investigation include: placebo (DRUG), indomethacin (DRUG).

Who is sponsoring clinical trial NCT00033917?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00033917 being conducted?

This trial has 3 study locations across Connecticut, Maine, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prematurity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00033917's enrollment target sits among peer trials

630 2nd of 21 the highest of 21 other Prematurity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prematurity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04704921 · 630 participants · Phase 2

    Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

  • NCT04707729 · 630 participants · NA

    ROX Index for the Timing of Intubation in Nasal High Flow

  • NCT05061550 · 630 participants · Phase 2

    Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • NCT05224440 · 630 participants · NA

    National Sponsorship Program for Transitioning Service Members

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00033917, the US trial registry maintained by the National Library of Medicine. NCT00033917 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.